vs
Side-by-side financial comparison of LifeStance Health Group, Inc. (LFST) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $382.2M, roughly 1.9× LifeStance Health Group, Inc.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs 3.1%, a 16.0% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 17.4%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $46.6M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 12.8%).
Lifestance Health (Lifestance) is an American outpatient behavioral health services provider. They provide their services in person and via tele-health. Their services include therapy, psychiatry, TMS, and ketamine therapies. They have landed in lawsuits multiple times over labor violations, leaking of customer information, and misleading investors.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
LFST vs MEDP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $382.2M | $708.5M |
| Net Profit | $11.7M | $135.1M |
| Gross Margin | — | — |
| Operating Margin | 4.7% | 21.6% |
| Net Margin | 3.1% | 19.1% |
| Revenue YoY | 17.4% | 32.0% |
| Net Profit YoY | 264.1% | 15.5% |
| EPS (diluted) | — | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $382.2M | $708.5M | ||
| Q3 25 | $363.8M | $659.9M | ||
| Q2 25 | $345.3M | $603.3M | ||
| Q1 25 | $333.0M | $558.6M | ||
| Q4 24 | $325.5M | $536.6M | ||
| Q3 24 | $312.7M | $533.3M | ||
| Q2 24 | $312.3M | $528.1M | ||
| Q1 24 | $300.4M | $511.0M |
| Q4 25 | $11.7M | $135.1M | ||
| Q3 25 | $1.1M | $111.1M | ||
| Q2 25 | $-3.8M | $90.3M | ||
| Q1 25 | $709.0K | $114.6M | ||
| Q4 24 | $-7.1M | $117.0M | ||
| Q3 24 | $-6.0M | $96.4M | ||
| Q2 24 | $-23.3M | $88.4M | ||
| Q1 24 | $-21.1M | $102.6M |
| Q4 25 | 4.7% | 21.6% | ||
| Q3 25 | 2.0% | 21.5% | ||
| Q2 25 | -0.9% | 20.9% | ||
| Q1 25 | 0.5% | 20.3% | ||
| Q4 24 | 0.3% | 23.4% | ||
| Q3 24 | 0.0% | 21.1% | ||
| Q2 24 | -5.1% | 19.9% | ||
| Q1 24 | -5.6% | 20.4% |
| Q4 25 | 3.1% | 19.1% | ||
| Q3 25 | 0.3% | 16.8% | ||
| Q2 25 | -1.1% | 15.0% | ||
| Q1 25 | 0.2% | 20.5% | ||
| Q4 24 | -2.2% | 21.8% | ||
| Q3 24 | -1.9% | 18.1% | ||
| Q2 24 | -7.5% | 16.7% | ||
| Q1 24 | -7.0% | 20.1% |
| Q4 25 | — | $4.65 | ||
| Q3 25 | — | $3.86 | ||
| Q2 25 | — | $3.10 | ||
| Q1 25 | — | $3.67 | ||
| Q4 24 | — | $3.67 | ||
| Q3 24 | — | $3.01 | ||
| Q2 24 | — | $2.75 | ||
| Q1 24 | — | $3.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $248.6M | $497.0M |
| Total DebtLower is stronger | $282.8M | — |
| Stockholders' EquityBook value | $1.5B | $459.1M |
| Total Assets | $2.2B | $2.0B |
| Debt / EquityLower = less leverage | 0.19× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $248.6M | $497.0M | ||
| Q3 25 | $203.9M | $285.4M | ||
| Q2 25 | $188.9M | $46.3M | ||
| Q1 25 | $134.3M | $441.4M | ||
| Q4 24 | $154.6M | $669.4M | ||
| Q3 24 | $102.6M | $656.9M | ||
| Q2 24 | $87.0M | $510.9M | ||
| Q1 24 | $49.5M | $407.0M |
| Q4 25 | $282.8M | — | ||
| Q3 25 | $284.6M | — | ||
| Q2 25 | $286.4M | — | ||
| Q1 25 | $288.2M | — | ||
| Q4 24 | $290.0M | — | ||
| Q3 24 | $287.3M | — | ||
| Q2 24 | $288.0M | — | ||
| Q1 24 | $288.8M | — |
| Q4 25 | $1.5B | $459.1M | ||
| Q3 25 | $1.5B | $293.6M | ||
| Q2 25 | $1.5B | $172.4M | ||
| Q1 25 | $1.5B | $593.6M | ||
| Q4 24 | $1.4B | $825.5M | ||
| Q3 24 | $1.4B | $881.4M | ||
| Q2 24 | $1.4B | $763.6M | ||
| Q1 24 | $1.4B | $671.5M |
| Q4 25 | $2.2B | $2.0B | ||
| Q3 25 | $2.1B | $1.8B | ||
| Q2 25 | $2.1B | $1.6B | ||
| Q1 25 | $2.1B | $1.9B | ||
| Q4 24 | $2.1B | $2.1B | ||
| Q3 24 | $2.1B | $2.1B | ||
| Q2 24 | $2.1B | $1.9B | ||
| Q1 24 | $2.1B | $1.8B |
| Q4 25 | 0.19× | — | ||
| Q3 25 | 0.19× | — | ||
| Q2 25 | 0.19× | — | ||
| Q1 25 | 0.20× | — | ||
| Q4 24 | 0.20× | — | ||
| Q3 24 | 0.20× | — | ||
| Q2 24 | 0.20× | — | ||
| Q1 24 | 0.20× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $57.6M | $192.7M |
| Free Cash FlowOCF − Capex | $46.6M | $188.1M |
| FCF MarginFCF / Revenue | 12.2% | 26.6% |
| Capex IntensityCapex / Revenue | 2.9% | 0.6% |
| Cash ConversionOCF / Net Profit | 4.93× | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | $110.0M | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $57.6M | $192.7M | ||
| Q3 25 | $27.3M | $246.2M | ||
| Q2 25 | $64.4M | $148.5M | ||
| Q1 25 | $-3.1M | $125.8M | ||
| Q4 24 | $62.3M | $190.7M | ||
| Q3 24 | $22.7M | $149.1M | ||
| Q2 24 | $44.1M | $116.4M | ||
| Q1 24 | $-21.8M | $152.7M |
| Q4 25 | $46.6M | $188.1M | ||
| Q3 25 | $17.0M | $235.5M | ||
| Q2 25 | $56.6M | $142.4M | ||
| Q1 25 | $-10.3M | $115.8M | ||
| Q4 24 | $56.0M | $183.0M | ||
| Q3 24 | $17.7M | $138.5M | ||
| Q2 24 | $39.0M | $103.5M | ||
| Q1 24 | $-26.9M | $147.2M |
| Q4 25 | 12.2% | 26.6% | ||
| Q3 25 | 4.7% | 35.7% | ||
| Q2 25 | 16.4% | 23.6% | ||
| Q1 25 | -3.1% | 20.7% | ||
| Q4 24 | 17.2% | 34.1% | ||
| Q3 24 | 5.7% | 26.0% | ||
| Q2 24 | 12.5% | 19.6% | ||
| Q1 24 | -9.0% | 28.8% |
| Q4 25 | 2.9% | 0.6% | ||
| Q3 25 | 2.8% | 1.6% | ||
| Q2 25 | 2.2% | 1.0% | ||
| Q1 25 | 2.2% | 1.8% | ||
| Q4 24 | 1.9% | 1.4% | ||
| Q3 24 | 1.6% | 2.0% | ||
| Q2 24 | 1.6% | 2.4% | ||
| Q1 24 | 1.7% | 1.1% |
| Q4 25 | 4.93× | 1.43× | ||
| Q3 25 | 25.34× | 2.22× | ||
| Q2 25 | — | 1.65× | ||
| Q1 25 | -4.36× | 1.10× | ||
| Q4 24 | — | 1.63× | ||
| Q3 24 | — | 1.55× | ||
| Q2 24 | — | 1.32× | ||
| Q1 24 | — | 1.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LFST
Segment breakdown not available.
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
